Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Cellect Biotechnology Ltd. for the month of November 2016. The filing serves to incorporate by reference documents related to an extraordinary meeting of shareholders and Series-1 Stock Option holders scheduled for January 9, 2017.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding corporate governance and does not contain financial statements or performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The primary content relates to the scheduling of a shareholder meeting and the submission of a Registration Statement on Form S-8 filed on November 28, 2016.
Guidance, Outlook, and Corporate Actions
The filing details the following corporate actions and proposals to be voted upon at the January 9, 2017 meeting:
- Notice and Proxy Statement regarding the extraordinary meeting.
- Proposal to approve an "Amended and Restated Compensation Policy for Company Office Holders."
- Procedures for voting in person or by proxy for ordinary shares, American depository shares, and Series-1 Stock Options.
The filing does not contain management commentary on future financial guidance, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the date and agenda of the extraordinary shareholder meeting scheduled for January 9, 2017.
- Review the attached "Amended and Restated Compensation Policy for Company Office Holders" (Exhibit A) for details on executive compensation changes.
- Confirm the status of the Form S-8 Registration Statement (No. 333-214817) filed on November 28, 2016, which is incorporated by reference.
- Note that this filing contains no financial performance data; refer to the most recent Form 20-F for financial metrics.